We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Approves ViiV Healthcare’s Combination HIV Drug Triumeq

FDA Approves ViiV Healthcare’s Combination HIV Drug Triumeq

August 29, 2014

Triumeq (abacavir/lamivudine/dolutegravir) is the first fixed-dose combination HIV therapy approved in the U.S. that contains dolutegravir, which the FDA approved last August as a single drug under the name Tivicay.

"Although single-pill regimens have been available to people living with HIV for some time, Triumeq offers many people living with HIV the option of a single-pill regimen that combines dolutegravir with abacavir and lamivudine," ViiV spokesman Marc Meacham said.

The agency’s approval was based on data from two clinical trials in which 8 percent more patients given Triumeq’s three components showed undetectable viral loads than patients given Bristol-Myers Squibb and Gilead Sciences’ Atripla (efavirenz, emtricitabine and tenofovir).

Dolutegravir is an integrase inhibitor that blocks viral DNA from entering human CD4 immune cells. Lamivudine and abacavir have been available since 1995 and 2004, respectively, and both are reverse transcriptase inhibitors that block transcription of viral RNA into DNA.

The European Medicines Agency approved dolutegravir in January, but a decision on authorization for the combination drug Triumeq is still pending there, as it is in Australia, Brazil and Canada.

ViiV, which was created by GlaxoSmithKline, Pfizer and Shionogi to develop HIV therapies, generated roughly $2.3 billion in sales last year, GSK said.

Triumeq joins a handful of other once-daily HIV therapies, including Gilead Sciences’ Complera (rilpivirine/tenofovir/emtricitabine), Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir) and Truvada (emtricitabine/tenofovir disoproxil fumarate). — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • WhiteHouse.gif

    President Biden Issues Executive Order on U.S. Supply Chain

  • roche.gif

    Priority Healthcare Settles Diabetes Test Lawsuit with Roche for $43 Million

  • Effective text

    Pfizer/BioNTech Vaccine Equally Effective for All Age Groups, Israeli Study Says

  • Siemens Healthineers logo

    Siemens Healthineers’ COVID-19 Antigen Lab Test Receives CE Mark

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing